Genetically Modified T-Cells for Pancreatic Cancer
Trial Summary
What is the purpose of this trial?
This trial tests a new treatment for advanced pancreatic cancer using modified immune cells from the patient. These cells are changed to better recognize and attack cancer cells. The goal is to find the best dose and see if this approach can help patients whose cancer has spread.
Research Team
Elena Chiorean
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Eligibility Criteria
Adults with metastatic pancreatic ductal adenocarcinoma who've had at least one systemic therapy can join. They must have a life expectancy over 3 months, be willing to undergo tumor biopsies, and not have received recent treatments that could interfere. Participants need properly functioning major organs, no severe autoimmune diseases or organ transplants, and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepletion Chemotherapy
Patients receive cyclophosphamide and fludarabine intravenously on days -5, -4, and -3 or optionally bendamustine on days -4 and -3 prior to the first T cell infusion
T-Cell Therapy
Patients receive FH-TCR-Tᴍsʟɴ intravenously over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Autologous Mesothelin-specific TCR-T Cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fred Hutchinson Cancer Center
Lead Sponsor
Fred Hutchinson Cancer Research Center
Lead Sponsor
Lonza Walkersville, Inc.
Industry Sponsor